 |  |
 |  |  | |||||||
|
--- Aspirin Risks In Healthy Individuals
madiba wrote: > Couple more degrees and you may even learn to usenet.. > Thats four (4) replies to this post up to now! ISP's and/or newsreaders sometimes seem to "hiccup". I've seen that on other newsgroup/posters. J
Roman Bystrianyk wrote: > > http://www.healthsentinel.com/org_news.php?event=org_news_print_list_item&id=16 > > Roman Bystrianyk, "Aspirin Risks In Healthy Individuals", Health > Sentinel, January 16, 2005, > > Felix Hoffman at Bayer Industries synthesized aspirin over 100 years > ago. Today there have been many ads promoting aspirin's potential to > reduce the risk of heart attack and stroke in certain people. However, > the decision to use aspirin as a preventative is not as simple as it > looks. What generally has not been analyzed are the risks and costs > associated with aspirin therapy. > > In the January issue of The Annals of Pharmacotherapy the authors > analyze the lifetime cumulative risk, the potential negative effects on > quality-adjusted-life-years (QALYs), life expectancy, and cost of > aspirin therapy. The authors construct a model of healthy individuals > starting at age 50 taking a 325 mg enteric-coated daily aspirin. Based > on numerous references the authors take into account adverse effects > such as upper gastrointestinal bleeding, quality of life factor, and > aspirin cost. > > Based on their analysis, aspirin therapy only had a modest negative > effect on both QALYs and life expectancy. The average lifetime cost was > determined to be $460 per person. > > However, the authors found that, "for every 15 healthy 50-year-old > men started on aspirin therapy, one will have a complication in his > lifetime; for every 556 individuals started on aspirin therapy, one > will die from complications." Comparison of death risk of lifetime > aspirin therapy (1 in 556) versus other mortality risks were listed as > follows: hip surgery (1 in 345), cardiac catheterization (1 in 500), > general anesthesia (1 in 3,685), annual accidents (1 in 3,014), food > poisoning (1 in 56,424), sky diving (1 in 70,130 per dive), and yearly > driving with a cell phone (1 in 76,900). > > The authors also note that, "starting aspirin at an earlier age > resulted in a larger absolute reduction in both QALYs and life > expectancy, increased cost, and not surprisingly, a greater number of > complications." > > The authors also analyzed the use of proton pump inhibitors (PPIs) to > reduce the aspirin risk. They determined a modest increase in quality > of life and life expectancy, but at a substantial increase in cost. The > addition of PPIs resulted in an increase from an average lifetime cost > of $460 per person to $18,400. > > The authors do not attempt to incorporate all the potential benefits of > aspirin, as the aim of the study was to determine the risk. The authors > also note that, "although good published data exist to accurately > model the drawbacks of aspirin therapy, the benefits of aspirin in > cancer chemoprevention are preliminary at best and will likely not be > apparent for at least 10 years of aspirin therapy. Short-term data for > the efficacy of aspirin for the prevention of primary coronary events > exist, but long-term data are currently unavailable." > SOURCE: The Annals of Pharmacotherapy, January 2005 >From their abstract: METHODS: A computer-based decision-analytic model was constructed. In this model, healthy individuals taking aspirin were assumed to receive no advantages from the aspirin, but were at risk of developing its associated complications. Individuals took 325 mg of enteric-coated aspirin every day until death, discontinuing therapy only if an aspirin-induced complication occurred. The analysis was performed from a societal perspective, starting at age 50 years. Extensive sensitivity analyses were performed. Their model is flawed from the outset with the assumption that there are "no advantages from aspirin." At His service, Andrew -- Andrew B. Chung, MD/PhD Board-Certified Cardiologist ** Suggested Reading: (1) http://makeashorterlink.com/?L26062048 (2) http://makeashorterlink.com/?O2F325D1A (3) http://makeashorterlink.com/?X1C62661A (4) http://makeashorterlink.com/?U1E13130A (5) http://makeashorterlink.com/?K6F72510A (6) http://makeashorterlink.com/?I24E5151A (7) http://makeashorterlink.com/?I22222129
The authors do not attempt to incorporate any of the potential benefits of aspirin. On the contrary, as the aim of the study was to determine the risk, all complication rates attributable to aspirin from numerous scientific sources were utilized. The authors note that, "although good published data exist to accurately model the drawbacks of aspirin therapy, the benefits of aspirin in cancer chemoprevention are preliminary at best and will likely not be apparent for at least 10 years of aspirin therapy. Short-term data for the efficacy of aspirin for the prevention of primary coronary events exist, but long-term data are currently unavailable."
Roman Bystrianyk wrote: > > The authors do not attempt to incorporate any of the potential benefits > of aspirin. On the contrary, as the aim of the study was to determine > the risk, all complication rates attributable to aspirin from numerous > scientific sources were utilized. The authors note that, "although > good published data exist to accurately model the drawbacks of aspirin > therapy, the benefits of aspirin in cancer chemoprevention are > preliminary at best and will likely not be apparent for at least 10 > years of aspirin therapy. Short-term data for the efficacy of aspirin > for the prevention of primary coronary events exist, but long-term data > are currently unavailable." It remains a flaw in their study to ignore the proven benefits of aspirin. The short-term benefit of MI and CVA prevention leads to the long-term consequences of survival which will impact upon the mathematical modeling. At His service, Andrew -- Andrew B. Chung, MD/PhD Board-Certified Cardiologist ** Suggested Reading: (1) http://makeashorterlink.com/?L26062048 (2) http://makeashorterlink.com/?O2F325D1A (3) http://makeashorterlink.com/?X1C62661A (4) http://makeashorterlink.com/?U1E13130A (5) http://makeashorterlink.com/?K6F72510A (6) http://makeashorterlink.com/?I24E5151A (7) http://makeashorterlink.com/?I22222129 Start « Previous 1 2 3 4 5 Related Discussion: Music and Chronic Pain (1 posts) bone growth / lactoferrin / iron (1 posts) Low Adherence to Guidelines for Nephropathy and Hypertension in Diabetics (1 posts) Are you a STAY-AT-HOME MOM? (1 posts) Top Discussions From Our Archives Rheumatoid Arthritis Attacks the Heart I can teach anyone how to get what they want out of life (OT) Are we a nation at risk from the flu? Alternative to Vioxx and Other Medications Hearing loss / iron / superficial siderosis Other Discussion Categories Diabetes Symptoms Health Care Policy Health Care Providers HMO Arthritis Symptoms Oops!!! Unexpected Error While Reading the Feed
|
| ||||||||
 |  |
